Rajesh Krishnan - Jan 20, 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Technology Officer
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Jan 20, 2022
Transactions value $
$0
Form type
4
Date filed
1/24/2022, 03:00 PM
Previous filing
Jan 5, 2022
Next filing
Aug 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +177K $0.00 177K Jan 20, 2022 Common Stock 177K $1.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.